Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibitionNathalie Jacque, Didier Bouscary, Estelle Saland et al.|Blood|2015Cited by 383
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathwaysJérôme Tamburini, Didier Bouscary, Nicolas Chapuis et al.|Blood|2007Cited by 252
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapyMarco Cerrano, Raphaël Itzykson, Matthieu Duchmann et al.|Leukemia|2020Cited by 20